Zymeworks Inc.

ZYME

US98985Y1082

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 04:00:00 2026-01-16 pm EST			5-day change	1st Jan Change
23.47 ^USD	-0.68%		+1.29%	-10.86%

Jan. 14	Zymeworks Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 03:00 PM
Jan. 12	Zymeworks Makes Leadership, Board Changes; Begins CFO Search	MT

Zymeworks Commences Strategic Initiative for Licensed Products to Enhance Future Cash Flows

Published on 11/18/2025 at 04:11 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Zymeworks Inc.

Jan. 14	Zymeworks Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 03:00 PM
Jan. 12	Zymeworks Makes Leadership, Board Changes; Begins CFO Search	MT
Jan. 12	Zymeworks Inc. Announces Management Changes	CI
Jan. 12	Zymeworks Inc. Announces Chief Financial Officer Changes, Effective January 9, 2026	CI
Jan. 11	Zymeworks outlines strategic priorities and outlook for 2026	RE
Jan. 06	Zymeworks Inc. Announces Positive Efficacy and Safety Results from the Phase 3 HERIZON-GEA-01 Trial Evaluating Ziihera	CI
Dec. 22	Zymeworks Insider Sold Shares Worth $1,284,311, According to a Recent SEC Filing	MT
Dec. 17	Truist Initiates Zymeworks at Buy With $40 Price Target	MT
Dec. 03	Zymeworks Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 03:15 PM
Nov. 21	B. Riley Raises Price Target on Zymeworks to $40 From $30, Keeps Buy Rating	MT
Nov. 18	Zymeworks Inc. - Shareholder/Analyst Call
Nov. 18	Zymeworks Inc. authorizes a Buyback Plan.	CI
Nov. 18	Zymeworks Inc. announces an Equity Buyback for $125 million worth of its shares.	CI
Nov. 18	Zymeworks Announces Board and Executive Changes	CI
Nov. 18	Zymeworks Commences Strategic Initiative for Licensed Products to Enhance Future Cash Flows	MT
Nov. 18	Zymeworks says authorizes $125 million share repurchase plan	RE
Nov. 17	Top Midday Gainers	MT
Nov. 17	Zymeworks Inc. Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera	CI
Nov. 17	Traders Eye Delayed Jobs Report, Nvidia Earnings, Stifling US Equity Futures Pre-Bell	MT
Nov. 17	Zymeworks' Phase 3 Trial for Gastroesophageal Cancer Treatment Shows Significant Improvement in Progression-Free Survival	MT
Nov. 17	Top Premarket Gainers	MT
Nov. 17	Zymeworks, Jazz Pharmaceuticals Shares Rise Following Positive Phase 3 Results for Cancer Treatment	DJ
Nov. 17	Zymeworks announces positive Herizon-GEA-01 phase 3 results supporting Ziihera as HER2-targeted agent-of-choice and new standard of care in first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma	RE
Nov. 06	Zymeworks Inc., Q3 2025 Earnings Call, Nov 06, 2025
Nov. 06	Tranche Update on Zymeworks Inc.'s Equity Buyback Plan announced on August 1, 2024.	CI

Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.

Employees

263

Sector

Biotechnology & Medical Research

Calendar

Mar. 10 - Q4 2025 Earnings Release (Projected)

More about the company